COMBINATION CANCER TREATMENTS UTILIZING SYNTHETIC OLIGONUCLEOTIDES AND EGFR-TKI INHIBITORS

摘要

The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a synthetic oligonucleotide.

主权项

1. A method for treating a subject having a cancer, the method comprising:
administering an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) agent to the subject; and administering a synthetic oligonucleotide including the sequence of a microRNA selected from miR-34, miR-124, miR-126, miR-147, miR-215, and microRNAs listed in Appendix A as SEQ ID NOs:8-122 to the subject, wherein if the EGFR-TKI agent is gefitinib, the microRNA is not miR-126.